These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35348408)

  • 41. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
    Nolte H; Pavord I; Backer V; Spector S; Shekar T; Gates D; Nair P; Hargreave F
    Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
    Heo YA
    Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.
    Sekerel BE; Nell H; Laki I; Pak T; Contreras E; Kolarz A; D'Andrea P; Manga V; Jain M; Vaidya S; Valentin M; Sen B
    Clin Drug Investig; 2023 Sep; 43(9):719-728. PubMed ID: 37682405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma.
    Karpel JP; Nelson H
    Curr Med Res Opin; 2007 Nov; 23(11):2897-911. PubMed ID: 17922978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 3 study evaluating the safety and efficacy of a pediatric dose of mometasone furoate with and without formoterol for persistent asthma.
    Weinstein CLJ; Gates D; Zhang X; Varnell T; Mok W; Vermeulen JH; Amar NJ; Jain N
    Pediatr Pulmonol; 2020 Apr; 55(4):882-889. PubMed ID: 32022483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.
    Weinstein SF; Corren J; Murphy K; Nolte H; White M;
    Allergy Asthma Proc; 2010; 31(4):280-9. PubMed ID: 20687982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
    Plate T; Friedrich FW; Beier J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1335-1347. PubMed ID: 32606643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study.
    Hozawa S; Ohbayashi H; Tsuchiya M; Hara Y; Lee LA; Nakayama T; Tamaoki J; Fowler A; Nishi T
    J Asthma Allergy; 2021; 14():809-819. PubMed ID: 34262299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis.
    Zhang Q; Zhang H; Wang J; Ruan Z; Dai Y; Xia Z; Lv Q
    Heart Lung; 2021; 50(4):532-541. PubMed ID: 33865004
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.
    Ferguson GT; Taylor AF; Thach C; Wang Q; Schubert-Tennigkeit AA; Patalano F; Banerji D
    Chronic Obstr Pulm Dis; 2016 Aug; 3(4):716-728. PubMed ID: 28848898
    [No Abstract]   [Full Text] [Related]  

  • 60. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.